Publications by authors named "D Roggenbuck"
Article Synopsis
- Antimicrobial autoantigenic glycoprotein 2 (GP2) plays a significant role in the immune system and is linked to the gut microbiome, but its systemic effects and associations are not fully understood.
- In a study involving 2,812 participants, higher fecal GP2 levels were found in those with a higher body mass index and smokers, while lower levels were associated with healthier factors, such as good pancreatic function and diet.
- Increased GP2 levels correlated with less gut microbial diversity, higher systemic inflammation, and a shift towards potentially harmful bacteria, suggesting that GP2 could serve as a biomarker for gut health and inflammation.
Background: Glycoprotein-2 (GP2) IgA is a predictor of disease severity in primary sclerosing cholangitis (PSC). We examined GP2's occurrence in the biliary tract, the site of inflammation.
Methods: GP2 was analyzed using ELISA, immunoblotting, mass spectrometry, and immunohistochemistry.
Despite powerful DNA repair systems, oxidative damage/modification to DNA is an inevitable side effect of metabolism, ionizing radiation, lifestyle habits, inflammatory pathologies such as type-2 diabetes or metabolic syndrome, cancer and natural aging. One of the most common oxidative DNA modifications is 8-OHdG (8‑hydroxy-2'-deoxyguanosine), which is the most widely used marker in research and clinical diagnostics. 8-OHdG is easily and specifically detectable in various samples such as urine, plasma, cells and tissues via a large variety of methods like ELISA, HPLC, chromatographic methods, and immunochemistry.
View Article and Find Full Text PDFNeurodegenerative diseases (NDs) are characterized by abnormalities within neurons of the brain or spinal cord that gradually lose function, eventually leading to cell death. Upon examination of affected tissue, pathological changes reveal a loss of synapses, misfolded proteins, and activation of immune cells-all indicative of disease progression-before severe clinical symptoms become apparent. Early detection of NDs is crucial for potentially administering targeted medications that may delay disease advancement.
View Article and Find Full Text PDFBackground: Anti-glycoprotein 2 (anti-GP2) IgA and antineutrophil-cytoplasmic antibodies to proteinase 3 (PR3-ANCA) have been reported as predictive markers of cholangiocarcinoma (CCA) in patients with primary sclerosing cholangitis (PSC), but their prevalence in CCA patients without PSC remains unclear.
Methods: This study involved Asian discovery (n = 118) and European validation (n = 38) cohorts of CCA patients without PSC, alongside 49 Asian and 82 European pancreatic ductal adenocarcinoma (PDAC) patients, 21 with benign pancreatic neoplasms (BPN) and 45 with hepatocellular carcinoma (HCC), and 157 healthy controls (HC) from Asia and Europe. We analyzed the prevalence of PR3-ANCA, IgA and IgG against GP2 and GP2, and the CA19-9 levels.